PIOGLITAZONE THERAPY FOR INFLAMMATORY PATHWAY COMPONENT OF INSULIN RESISTANCE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine whether the thiazolidinedione(TZD) pioglitazone improves insulin sensitivity by causing beneficial alterations in components of the inflammatory signaling pathway, whether pioglitazone treatment prevents, or attenuates, fat-induced insulin resistance, and whether this is also due to drug induced favorable alterations in inflammatory pathway molecular components, determine the time course over which pioglitazone leads to a decrease in glucose, insulin, and FFA levels, as well as insulin sensitivity and adipose tissue remodeling to determine whether adipocyte remodeling occurs with drug treatment and whether this is a participatory mechanism in insulin sensitization, and whether pioglitazone attenuates abnormal kinetics of insulin action present in insulin resistance.